Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)-Reference-Cited by-同舟云学术

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

Published:2017-11-20 Issue:3 Volume:7 Page:e1395127
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Hoffmann Ricarda M.¹²,Coumbe Ben G. T.¹³,Josephs Debra H.¹⁴,Mele Silvia¹,Ilieva Kristina M.¹⁵,Cheung Anthony¹⁵,Tutt Andrew N.⁵,Spicer James F.⁴,Thurston David E.⁶⁷,Crescioli Silvia¹²,Karagiannis Sophia N.¹²⁵^ORCID

Affiliation:

1. St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Tower Wing, Guy's Hospital, London, United Kingdom

2. NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, King's College London, London, United Kingdom

3. School of Clinical Medicine, University College London Medical School, London, United Kingdom

4. School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Hospital, London, United Kingdom

5. Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Cancer Centre, London, United Kingdom

6. Institute of Pharmaceutical Science, King's College London, Britannia House, London, United Kingdom

7. Femtogenix Ltd, BioPark, Welwyn Garden City, Hertfordshire, United Kingdom

Funder

Breast Cancer Now

Cancer Research UK

Cancer Research UK Experimental Cancer Medicine Centre

Biotechnology and Biological Sciences Research Council (BBSRC)

DH | National Institute for Health Research/ Biomedical Research Centre

Medical Research Council (MRC)

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1395127

Reference78 articles.

1. Antibody-drug conjugates—an emerging class of cancer treatment

2. Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

3. Antibody–drug conjugates as novel anti-cancer chemotherapeutics

4. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

5. Rab GTPases as coordinators of vesicle traffic

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10

2. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments;Critical Reviews in Oncology/Hematology;2024-09

3. Precision targeting in oncology: The future of conjugated drugs;Biomedicine & Pharmacotherapy;2024-08

4. Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities;Pharmaceutical Science Advances;2024-08

5. Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review;Cancers;2024-07-27